Can 2 circulating blood biomarkers—amino-terminal prohormone of brain natriuretic peptide (NT-proBNP) and interleukin 1 receptor-like 1 (IL-1 RL1)—be quantified in newborns using minimal amounts of dried blood spot (DBS) samples with reliable results for the early detection of congenital heart disease (CHD) serious enough to require cardiac surgery during infancy? This evidence concerns the gene NPPB and coronary artery disorder.